TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05872295: IKS014 in Advanced Solid Tumors That Express HER2

Sponsor: Iksuda Therapeutics Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 165 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$2,450,448

Rescue Site Savings

+$1,602,216

Unlock Full NCT05872295 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05872295 Rescue Dossier →